CD274 and neoplasm: Typically, different levels of combination therapy remain the primary option, especially when considering factors like high tumor burden, immediate symptom relief, specific oncogene mutations, and good chemotherapy tolerance, as well as a slightly better OS improvement, although almost all guidelines and consensus proposing single immunotherapy for patients with PD-L1 TPS above 50%.335,339